These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 26892328)

  • 1. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis.
    Kennedy NA; Warner B; Johnston EL; Flanders L; Hendy P; Ding NS; Harris R; Fadra AS; Basquill C; Lamb CA; Cameron FL; Murray CD; Parkes M; Gooding I; Ahmad T; Gaya DR; Mann S; Lindsay JO; Gordon J; Satsangi J; Hart A; McCartney S; Irving P; ; Lees CW
    Aliment Pharmacol Ther; 2016 Apr; 43(8):910-923. PubMed ID: 26892328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy.
    Bots SJ; Kuin S; Ponsioen CY; Gecse KB; Duijvestein M; D'Haens GR; Löwenberg M
    Scand J Gastroenterol; 2019 Mar; 54(3):281-288. PubMed ID: 30907185
    [No Abstract]   [Full Text] [Related]  

  • 3. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
    Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP
    Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease.
    Mahmoud R; Savelkoul EHJ; Mares W; Goetgebuer R; Witteman BJM; de Koning DB; van Tuyl SAC; Minderhoud I; Lutgens MWMD; Akol-Simsek D; van Schaik FDM; Fidder HH; Jansen JM; van Boeckel PGA; Mahmmod N; Horjus-Talabur Horje CS; Römkens TEH; Colombel JF; Hoentjen F; Jharap B; Oldenburg B;
    Clin Gastroenterol Hepatol; 2023 Mar; 21(3):750-760.e4. PubMed ID: 36055567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
    Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
    Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice.
    Arenas A; Moreta MJ; Ordás I; Fernández-Clotet A; Caballol B; Gallego M; Vara A; Barastegui R; Giner A; Prieto C; Masamunt MC; Candia R; Ricart E
    Gastroenterol Hepatol; 2024; 47(7):673-682. PubMed ID: 37562767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of elective withdrawal of anti-tumour necrosis factor-α therapy in patients with Crohn's disease in established remission.
    Brooks AJ; Sebastian S; Cross SS; Robinson K; Warren L; Wright A; Marsh AM; Tsai H; Majeed F; McAlindon ME; Preston C; Hamlin PJ; Lobo AJ
    J Crohns Colitis; 2017 Dec; 11(12):1456-1462. PubMed ID: 25311864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal.
    Ben-Horin S; Chowers Y; Ungar B; Kopylov U; Loebstein R; Weiss B; Eliakim R; Del Tedesco E; Paul S; Roblin X
    Aliment Pharmacol Ther; 2015 Aug; 42(3):356-64. PubMed ID: 26032402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study.
    Song JH; Kang EA; Park SK; Hong SN; Kim YS; Bang KB; Kim KO; Lee HS; Kang SB; Shin SY; Song EM; Im JP; Choi CH;
    Gut Liver; 2021 Sep; 15(5):752-762. PubMed ID: 33767028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases.
    Pariente B; Laharie D
    Aliment Pharmacol Ther; 2014 Aug; 40(4):338-53. PubMed ID: 24957164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease.
    Torres J; Boyapati RK; Kennedy NA; Louis E; Colombel JF; Satsangi J
    Gastroenterology; 2015 Dec; 149(7):1716-30. PubMed ID: 26381892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
    Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
    Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
    Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission.
    Molander P; Färkkilä M; Salminen K; Kemppainen H; Blomster T; Koskela R; Jussila A; Rautiainen H; Nissinen M; Haapamäki J; Arkkila P; Nieminen U; Kuisma J; Punkkinen J; Kolho KL; Mustonen H; Sipponen T
    Inflamm Bowel Dis; 2014 Jun; 20(6):1021-8. PubMed ID: 24798636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents.
    Molander P; Färkkilä M; Kemppainen H; Blomster T; Jussila A; Mustonen H; Sipponen T
    Scand J Gastroenterol; 2017 Mar; 52(3):284-290. PubMed ID: 27806638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy.
    Gisbert JP; Marín AC; Chaparro M
    Aliment Pharmacol Ther; 2015 Aug; 42(4):391-405. PubMed ID: 26075832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
    Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
    Gisbert JP; Marín AC; Chaparro M
    Am J Gastroenterol; 2016 May; 111(5):632-47. PubMed ID: 27002797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.